Novo Nordisk A/S buy mohabbatein
Summary
This prediction ended on 26.10.17 with a price of €41.97. With a performance of 2.29%, the BUY prediction by mohabbatein for Novo Nordisk A/S closed with a slight gain. mohabbatein has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | -1.816% | -2.419% | 12.070% | 14.356% |
| iShares Nasdaq 100 | 4.333% | 8.073% | 32.493% | 59.393% |
| iShares Nikkei 225® | 0.657% | 1.234% | 2.682% | 5.342% |
| iShares S&P 500 | 2.968% | 4.613% | 26.496% | 49.719% |
Comments by mohabbatein for this prediction
In the thread Novo Nordisk A/S diskutieren
Einstiegschance nach negativem Analystenkommentar
Heute gibt Novo Nordisk etwas ab, nachdem sich HSBC skeptisch geäußert und mit 210 DKK ein extrem niedriges Kursziel ausgegeben hat. Eine Begründung wurde dafür freilich nicht gegeben.
Goldman, UBS und Morgan Stanley sind da deutlich optimistischer.
Der Aufwärtstrend sowie die Nachrichtenlage bleiben weiterhin intakt. Die Zukunftsaussichten im Diabetesbereich sowieso. Und die Pipeline ausserhalb des Kerngeschäfts beinhatet jede Menge Überraschungspotential.
BUY.
Stopped prediction by mohabbatein for Novo Nordisk A/S
Novo Nordisk A/S
08.09.16
02.02.17
02.02.17
